New AI model predicts TP53 mutations across 32 cancers. EGFR prediction models vary by ancestry. Breast pathology review finds AI improves accuracy but notes barriers.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
The U.S. five-year cancer survival rate reached 70% in 2025, creating 18.6 million survivors. Health systems are expanding survivorship care using advanced practice providers and investing over $4 billion in oncology infrastructure to meet growing demand.
The largest CAR-T trial for pediatric solid tumors has opened in the US and UK, enrolling up to 60 young patients across four sites. The NexTGen study targets relapsed or refractory cancers and focuses first on safety and feasibility.
Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on March 27, 2026, featuring discussions on epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming. The event continues collaboration between Dana-Farber and France's Gustave Roussy cancer center with support from L'Institut Servier and Medscape Medical Affairs.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
A CNIC study demonstrates that remote ischemic conditioning can protect the heart during anthracycline chemotherapy without compromising antitumor efficacy, while researchers explore additional methods to manage chemotherapy side effects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774104 |
A Structured Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation |
NOT_YET_RECRUITING | NA |
| NCT07735624 |
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer |
RECRUITING | PHASE2 |
| NCT07735442 |
BRIDGE-SIC Efficacy Trial |
NOT_YET_RECRUITING | NA |
| NCT07732140 |
Listen Aphasia Pilot Study |
NOT_YET_RECRUITING | NA |
| NCT07729150 |
Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes |
NOT_YET_RECRUITING | NA |
| NCT07714551 |
Zanzalintinib in Unresectable and Progressive MPGGs |
NOT_YET_RECRUITING | PHASE2 |
| NCT07710131 |
Neurocognitive Assessment CNSL and LGG |
NOT_YET_RECRUITING | NA |
| NCT07675967 |
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study |
RECRUITING | |
| NCT07663006 |
Breast and Cervical Cancer Stigma in Rwanda |
NOT_YET_RECRUITING | NA |
| NCT07662239 |
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention |
NOT_YET_RECRUITING | NA |
